Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing

Doximity (DOCS) recently closed at $68.50, up 2.48% and outperforming the S&P 500, though its stock has declined 10.16% over the past month. The company is projected to report strong growth for its upcoming earnings on November 6, 2025, with an estimated EPS of $0.38 (+26.67%) and revenue of $157.79 million (+15.32%) for the quarter, alongside positive full-year forecasts. Analysts currently rate DOCS with a Zacks Rank #2 (Buy), noting its Forward P/E of 44.12, which is slightly above its industry average, and a comparable PEG ratio of 3.21.

Analysis

Doximity (DOCS) recently closed at $68.50, marking a +2.48% daily gain and outperforming the S&P 500's 1.23% increase. This positive daily performance contrasts with a significant monthly decline of 10.16%, underperforming both the Medical sector and the broader S&P 500, indicating recent volatility ahead of its upcoming earnings report on November 6, 2025.

The company projects robust growth for the upcoming quarter, with EPS estimated at $0.38, a 26.67% year-over-year increase, and revenue expected to reach $157.79 million, up 15.32%. Full-year Zacks Consensus Estimates also forecast positive trends, with EPS growing 7.04% to $1.52 and revenue increasing 11.15% to $633.98 million, reflecting sustained business expansion.

Analyst sentiment remains positive, as evidenced by a Zacks Rank #2 (Buy) and an unchanged Zacks Consensus EPS estimate over the last 30 days. While Doximity trades at a Forward P/E of 44.12, a premium to its industry average of 40.8, its PEG ratio of 3.21 is slightly below the Medical Info Systems industry average of 3.3, suggesting its growth prospects are reasonably priced relative to its peers. The industry itself holds a strong Zacks Industry Rank of 55, placing it in the top 23% of all industries.

Key Decisions for Investors

• Investors should closely monitor Doximity's upcoming earnings report on November 6, 2025, as it will be a key catalyst following recent stock underperformance despite strong growth projections.
• Evaluate whether Doximity's projected earnings and revenue growth, coupled with its Zacks Rank #2 (Buy), justify its current valuation premium relative to the industry's average Forward P/E.
• Consider the company's position within the highly-ranked Medical Info Systems industry as a supportive factor for long-term investment, but remain cognizant of the stock's recent monthly decline.